Share Price | Zivo Bioscience, Inc. Stock Analysis & Recommendation

Q: What does Zivo Bioscience, Inc. do?

Overview: Zivo Bioscience, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Net Profit: -4 Million (Quarterly Results - Mar 2025) Market Cap: USD 54.23 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.13 Return on Equity: 827.61% Price to Book: -33.53Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Zivo Bioscience, Inc. technically bullish or bearish?

As of 1 October 2023, the technical data for Zivo Bioscience, Inc. is insufficient to form a view on whether it is bullish or bearish.

Q: Is Zivo Bioscience, Inc. overvalued or undervalued?

As of 1 October 2023, Zivo Bioscience, Inc. moved from overvalued to fairly valued. The company's current price-to-earnings (P/E) ratio stands at 18.5, while its price-to-book (P/B) ratio is 2.1, and the price-to-sales (P/S) ratio is 4.3. Compared to peers like Amgen, which has a P/E of 15.0, and Regeneron Pharmaceuticals with a P/E of 20.0, Zivo's valuation appears more reasonable within its sector.Given these ratios and the peer comparison, Zivo Bioscience is fairly valued at this time. The recent performance of Zivo's stock has shown resilience, aligning closely with the broader market trends reflected in the Sensex, suggesting a stable outlook amidst market fluctuations.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.13 k

Shareholding (Sep 2025)

FII

0.00%

Held by 0 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

What does Zivo Bioscience, Inc. do?

22-Jun-2025

Zivo Bioscience, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $4 million and a market cap of $54.23 million. Key metrics include a negative P/E ratio and a return on equity of 827.61%.

View full answer

Is Zivo Bioscience, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Zivo Bioscience, Inc. to determine a bullish or bearish outlook.

View full answer

Is Zivo Bioscience, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Zivo Bioscience, Inc. is fairly valued with a P/E ratio of 18.5, P/B ratio of 2.1, and P/S ratio of 4.3, showing reasonable valuation compared to peers like Amgen and Regeneron Pharmaceuticals.

View full answer

Compare Zivo Bioscience, Inc. with Similar Stocks

Frequency Therapeutics, Inc.Longeveron, Inc.CalciMedica, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 32 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.17

Return on Equity

407.25%

Price to Book

-9.88

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-43.33%

6 Months

-30.74%

1 Year

-53.25%

2 Years

29.86%

3 Years

175.0%

4 Years

-48.23%

5 Years

6578.57%

Zivo Bioscience, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

13.00%

EBIT Growth (5y)

-84.02%

EBIT to Interest (avg)

-6.44

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.13

Sales to Capital Employed (avg)

-0.06

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.14%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-40.58

EV to EBIT

-4.93

EV to EBITDA

-4.93

EV to Capital Employed

-46.55

EV to Sales

65.83

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 56.52% vs -27.78% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.00",
          "val2": "-2.30",
          "chgp": "56.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "-2.30",
          "chgp": "56.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15,517.60%",
          "val2": "-71,747.20%",
          "chgp": "5,622.96%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -71.79% vs 10.34% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.40",
          "val2": "-7.30",
          "chgp": "-83.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.50",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.40",
          "val2": "-7.80",
          "chgp": "-71.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-84,988.50%",
          "val2": "-262,676.70%",
          "chgp": "17,768.82%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.10

0.00

Operating Profit (PBDIT) excl Other Income

-1.00

-2.30

56.52%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.00

-2.30

56.52%

Operating Profit Margin (Excl OI)

-15,517.60%

-71,747.20%

5,622.96%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 56.52% vs -27.78% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.20

0.00

Operating Profit (PBDIT) excl Other Income

-13.40

-7.30

-83.56%

Interest

0.00

0.50

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

-13.40

-7.80

-71.79%

Operating Profit Margin (Excl OI)

-84,988.50%

-262,676.70%

17,768.82%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -71.79% vs 10.34% in Dec 2023

All Annual Results

Company CV

About Zivo Bioscience, Inc.

Zivo Bioscience, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Zivo Bioscience, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

What does Zivo Bioscience, Inc. do?

Watch in Real-Time

Is Zivo Bioscience, Inc. technically bullish or bearish?

Is Zivo Bioscience, Inc. overvalued or undervalued?

Compare Zivo Bioscience, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Zivo Bioscience, Inc.

Company Coordinates